Warfarin Dosing Calculator

What warfarin is and how it works

Warfarin (brand name Coumadin) is a vitamin K antagonist anticoagulant used to prevent and treat venous thromboembolism (DVT and PE), reduce stroke risk in atrial fibrillation, and protect patients with mechanical heart valves. It works by inhibiting the VKORC1 enzyme, which is responsible for recycling vitamin K into its active form. Without active vitamin K, the liver cannot produce clotting factors II, VII, IX and X, so the blood clots more slowly. The degree of anticoagulation is measured by the International Normalized Ratio (INR). A normal INR is approximately 1.0; the therapeutic range for most warfarin indications is 2.0-3.0, meaning clotting takes two to three times longer than normal.

How the initiation dose is estimated: the Gage clinical algorithm

The initiation mode uses the clinical (non-genetic) regression algorithm published by Gage et al. in Clinical Pharmacology and Therapeutics in 2008, derived from a derivation cohort of 1,015 anticoagulation clinic patients. It predicts ln(daily dose in mg) as a linear combination of body surface area, age, race, target INR, amiodarone co-administration, smoking status, and whether the indication is DVT or PE. The coefficients were: +0.425 per unit of BSA, -0.0075 per year of age, +0.156 for African-American race, +0.216 per unit of target INR, -0.257 if amiodarone is being used, +0.108 if the patient smokes, and +0.0784 if the indication is DVT or PE. Body surface area is calculated from weight and height using the DuBois formula: BSA (m2) = 0.007184 x weight (kg)^0.425 x height (cm)^0.725. The algorithm explained 21.5% of the variance in stable warfarin dose in the derivation cohort (17-22% across cohorts) -- useful as a starting estimate but no substitute for serial INR-guided titration.

How the INR-based dose adjustment works

The adjustment mode applies a standard maintenance nomogram to recommend a percentage change to the weekly dose based on the current INR and the target band. If the INR is well below the target, the dose is increased (typically 10-20%). If the INR is within the target band, the dose is continued unchanged. If the INR is above the target band, one or more doses may be held and the weekly dose reduced. The standard nomogram for the most common target (2.0-3.0) calls for: an increase of about 20% when INR is below 1.5; about 10% when INR is 1.5-1.9; no change when INR is 2.0-3.0; about 10% reduction when INR is 3.1-3.5; hold one dose and reduce by about 15% when INR is 3.6-4.0; and hold one to two doses and reduce by about 20% when INR is above 4.0. The 2.5-3.5 nomogram shifts these thresholds upward by 0.5 INR units accordingly. Two absolute safety thresholds override the nomogram at any target. For an INR between 4.5 and 10 without bleeding, CHEST 2012 guidance is to hold one or two doses and increase monitoring, but not to give vitamin K routinely. For an INR above 10 without bleeding, warfarin is held and vitamin K 2.5-5 mg is given by mouth, with the INR rechecked daily. Any INR accompanied by significant bleeding is treated as an emergency with four-factor prothrombin complex concentrate and intravenous vitamin K, not with a dose adjustment.

Factors that affect warfarin sensitivity

Warfarin has an unusually narrow therapeutic window and is affected by dozens of variables. Genetic factors are the most powerful: VKORC1 promoter polymorphisms account for about 33% of dose variance, and CYP2C9 variants (*2 and *3 alleles) account for another 22% by slowing S-warfarin hydroxylation. Clinical factors include age (older patients need lower doses), body size (larger patients need more), vitamin K intake (high dietary K reduces effect), liver disease (reduces clotting factor synthesis independently), and many drug interactions. Strong inducers of CYP2C9 such as rifampicin can double the required dose; strong inhibitors such as amiodarone, fluconazole, and metronidazole can halve it. Any change in diet, co-medication, or health status should prompt an early INR recheck.